

Editorial

Carcinogenesis and cancer prevention: the process and the disease deserve a better understanding

Gopala Kovvali

Address: Crohn's and Colitis Center of New Jersey, Department of Medicine, The University of Medicine and Dentistry of New Jersey Room 7023, 125 Paterson Street, Clinical Academic Building, New Brunswick NJ 08901, United States

E-mail: kovvalgk@umdnj.edu

Published: 15 November 2002

Received: 12 November 2002

Journal of Carcinogenesis 2002, 1:1

Accepted: 15 November 2002

This article is available from: <http://www.Carcinogenesis.com/content/1/1/1>

© 2002 Kovvali; licensee BioMed Central Ltd. This article is published in Open Access: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

The last few decades have seen a significant progress in the management of various cancers. In addition to traditional treatments such as radiation, surgery, and chemotherapy, several new approaches based on knowledge of biological processes have been developed and tested and are being constantly refined. It is ironic that while we are making progress in treating cancers, the incidence of cancers is increasing. This discomfiting fact suggests that perhaps the best way to fight cancer may be to prevent it from appearing in the first place.

A common question in the minds of scientists and physicians involved in research and treatment of cancer is how do we prevent it? The obvious answer comes from the age old saying that 'you are what you eat and breathe, and that in turn may answer the question of how our ancestors had much lower incidence of cancer.

As we, the scientists, are curious, we ask what are the substances in our food that are vital to maintain normal functioning of the cells in the body? A corollary to this question would be, could we identify those substances and supplement them into food to prevent and or reverse the process of cancer development.

The possibility of reversing cancer depends on the knowledge of the fundamental molecular changes that accompany the process of cancer development. The paradigm that cancer is a result of genetic changes and is, therefore,

not amenable to efforts to reverse it, seems to be giving way to a new concept that 'genetic changes are not necessarily permanently etched in cells and the wild type characteristics of the cells could be restored'. Results published in recent papers are encouraging and show a promise for a major paradigm shift [1–8].

Incidence of cancers of the gastrointestinal tract is increasing at an alarming rate. It is important to develop non-invasive methods of detecting precancerous and cancerous lesions. Development of sensitive and specific techniques for early diagnosis will have a far-reaching effect on reducing the incidence of and mortality from GI cancers in at-risk population.

Technological advances in the field of genomics and proteomics are responsible for a major thrust in understanding the complex molecular processes of cancer and for assessing the efficacy of various compounds-natural products and synthetic analogues. Complete sequencing of the human genome and identification of all human genes in near future will have far reaching influence on our understanding of complex processes like cancer and will lead to effective therapies.

In spite of all these advances in the treatment of cancer and knowledge of the processes responsible for the disease, there is a gap in the understanding of molecular events leading to cancer and mechanisms of action by anticancer agents. Generally speaking, the field of carcino-

genesis is far from being completely explored. Many novel ideas and concepts still need to be introduced into the field and the results of several provocative experiments are yet to be disseminated and shared. There is a need and greater scope for multidisciplinary research in the field. A forum for an accelerated publication of results and a free access to such publications is very important to the field. These are the considerations that led to the birth of a new online journal, **Journal of Carcinogenesis**.

I am very happy that several eminent researchers and physicians have agreed to be on the editorial board of this journal. The journal will branch into six sections headed by an editor who is an expert in that field. Steven Shiff will be in charge of organizing the section on diet and environmental carcinogenesis, Nitin Telang will be editor for Chemoprevention section, Yutaka Kohgo will head clinical and Preclinical studies, Hongua Li will edit Genomics and Proteomics, Kiron Das will edit a section on gastrointestinal carcinogenesis and Satya Narayan will be editing a section on DNA damage response and cell signaling.

I hope the new journal will receive your support and suggestions and you will consider it a journal worthy of publishing your exciting results.

References

1. Selivanova G, Kawasaki T, Ryabchenko L, Wiman KG: **Reactivation of mutant p53: a new strategy for cancer therapy**. *Semin Cancer Biol* 1998, **8**:369-378
2. Wiman KG: **New p53-based anti-cancer therapeutic strategies**. *Med Oncol* 1998, **15**:222-8
3. Blagosklonny MV: **P53: an ubiquitous target of anticancer drugs**. *Int J Cancer* 2002, **98**:161-6
4. Selivanova G: **Mutant p53: the loaded gun**. *Curr Opin Investig Drugs* 2001, **2**:1136-41
5. Hietanen S, Lain S, Krausz E, Blattner C, Lane DP: **Activation of p53 in Cervical carcinoma cells by small molecules**. *Proc Natl Acad Sci U SA* 2000, **97**:8501-6
6. Foster BA, Coffey HA, Morin MJ, Rastinejad F: **Pharmacological rescue of mutant p53 conformation and function**. *Science* 1999, **286**:2507-2510
7. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG, Selivanova G: **Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound**. *Nat Med* 2002, **8**:282-8
8. Sirchia SM, Ren M, Pili R, Sironi E, Somenzi G, Ghidoni R, Toma S, Nicolo G, Sacchi N: **Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer**. *Cancer Res* 2002, **62**:2455-61

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMedcentral will be the most significant development for disseminating the results of biomedical research in our lifetime."

Paul Nurse, Director-General, Imperial Cancer Research Fund

Publish with **BMC** and your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours - you keep the copyright

Submit your manuscript here:

<http://www.biomedcentral.com/manuscript/>



BioMedcentral.com

editorial@biomedcentral.com